The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...
Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback